The newly appointed Vice President of Business Development and Senior Vice President of Clinical Development bring more than 20 years of industry experience to Sanifit.
Palma, Spain and San Diego, USA, June 01, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announces two new additions to its executive team, effective immediately. Hans Christian Keller joins the Company as Vice President of Business Development, and Laura Williams as Senior Vice President of Clinical Development.
Hans Christian is an executive with more than 20 years of experience in business development and commercial roles within the global pharmaceutical industry. Hans Christian joins Sanifit from H. Lundbeck A/S, where he has served as Global Senior Director Business Development since 2015, following seven years in business development roles of increasing responsibility. During his time at Lundbeck, Hans Christian has been involved in numerous transactions spanning academic organizations and small and large pharmaceutical and biotech companies, including licensing-in and licensing-out deals, mergers and acquisitions, asset acquisitions and equity deals for projects / products in development and in commercial stages. His notable management experience includes working as lead negotiator on the acquisition of Alder Biopharmaceuticals by Lundbeck in 2019. Hans Christian obtained a Postgraduate Diploma in Business (HD-O) at Copenhagen Business School after completing his degree in Chemical Engineering at the Technical University of Denmark.
Laura joins Sanifit with over 20 years of experience in early and late-stage drug development across a wide range of therapeutic areas. In her previous role, Laura served as Senior Vice President and Head of Clinical Development and Biostatistics at AMAG Pharma since 2017. In this role, Laura oversaw the clinical development strategy for numerous clinical compounds, including ongoing due diligence on the development of several products, in addition to successfully obtaining FDA marketing approval for bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Prior to joining AMAG, Laura spent 18 years at AbbVie (formerly Abbott Laboratories) in roles of increasing responsibility, leading clinical development programs in multiple therapeutic areas spanning all phases of drug development. Laura attended medical school at the University of Iowa College of Medicine, where she earned her MD, before earning her Public Health degree in Epidemiology at the University of Washington, where she also enjoyed a fellowship in infectious diseases.
Joan Perelló, CEO of Sanifit, commented, “I am delighted to welcome Hans Christian and Laura to the Sanifit team. Their backgrounds bring extensive experience and expertise to strengthen our clinical and business operations as we advance the development of our calcification therapies. Hans Christian and Laura will be instrumental in guiding Sanifit forward as our treatments advance in order to change patients’ lives, and we are excited to work with them.”
– – –
More about Sanifit: www.sanifit.com